Loading...
Vir Biotechnology Community
NasdaqGS:VIR Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
Community Investing Ideas
Strong Clinical Advances In Oncology And Hepatitis Delta Will Secure Future Success
Key Takeaways ECLIPSE Phase III program in hepatitis delta and oncology advancements promise revenue and earnings growth through new treatments and diversified revenue streams. Restructuring to reduce expenses and strategic capital allocation enhance financial stability, ensuring long-term sustainability and support for clinical development.
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
US$17.63
65.7% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
40.65% p.a.
Profit Margin
12.02%
Future PE
435.77x
Share price in 2028
US$21.24